Resistance to ER or HER2-targeted therapies remains a major concern in tumor-relapse/refractory cases, and effort is being made to understand the mechanism of resistance and to re-sensitize or obstruct disease progression through the use of novel therapies and/or combinatorial treatment approaches [30,75,76]. Here, ERBB2 is linked to neoplasm.